Research and Practice in Thrombosis and Haemostasis

Papers
(The H4-Index of Research and Practice in Thrombosis and Haemostasis is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
ArticleCitations
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis353
A proposal for staging COVID‐19 coagulopathy76
Venous thromboembolism in critically Ill patients with COVID‐19: Results of a screening study for deep vein thrombosis73
Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality67
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)58
Sexism in the management of bleeding disorders56
Tranexamic acid evidence and controversies: An illustrated review50
Heparin‐induced thrombocytopenia with thrombosis in COVID‐19 adult respiratory distress syndrome49
Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients46
Thrombosis and coagulopathy in COVID‐19: An illustrated review46
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study43
Potential role of platelets in COVID‐19: Implications for thrombosis40
Comparison of the coagulopathies associated with COVID‐19 and sepsis39
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis38
Posters Abstracts36
Abstract35
Essential aspects of the follow‐up after acute pulmonary embolism: An illustrated review35
Abstracts34
Anticoagulation practice patterns in COVID‐19: A global survey34
Protease‐activated receptors: An illustrated review32
The role of platelets in sepsis31
Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐1931
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)30
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries29
Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features28
Hormonal therapies and venous thrombosis: Considerations for prevention and management26
0.059876918792725